9966 logo

Alphamab Oncology SZSC:9966 Stock Report

Last Price

HK$3.46

Market Cap

HK$3.3b

7D

1.5%

1Y

-44.2%

Updated

23 Dec, 2024

Data

Company Financials +

9966 Stock Overview

A clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. More details

9966 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Alphamab Oncology Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alphamab Oncology
Historical stock prices
Current Share PriceHK$3.46
52 Week HighHK$6.71
52 Week LowHK$2.00
Beta0.36
1 Month Change-20.64%
3 Month Change26.74%
1 Year Change-44.19%
3 Year Change-75.04%
5 Year Changen/a
Change since IPO-79.26%

Recent News & Updates

Recent updates

Shareholder Returns

9966HK BiotechsHK Market
7D1.5%-3.9%-0.5%
1Y-44.2%-5.7%19.9%

Return vs Industry: 9966 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.

Return vs Market: 9966 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 9966's price volatile compared to industry and market?
9966 volatility
9966 Average Weekly Movement18.4%
Biotechs Industry Average Movement11.1%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 9966's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 9966's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
2008429Ting Xuwww.alphamabonc.com

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company’s product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders.

Alphamab Oncology Fundamentals Summary

How do Alphamab Oncology's earnings and revenue compare to its market cap?
9966 fundamental statistics
Market capHK$3.33b
Earnings (TTM)-HK$229.80m
Revenue (TTM)HK$272.69m

12.2x

P/S Ratio

-14.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9966 income statement (TTM)
RevenueCN¥255.87m
Cost of RevenueCN¥52.88m
Gross ProfitCN¥202.99m
Other ExpensesCN¥418.62m
Earnings-CN¥215.63m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.22
Gross Margin79.33%
Net Profit Margin-84.27%
Debt/Equity Ratio19.6%

How did 9966 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 11:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alphamab Oncology is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wangbin ZhouCitigroup Inc
null nullCLSA
null nullGuoyuan Securities (HK) Ltd